- Home
- ASTH vs OCS Comparison
ASTH vs OCS Comparison
Compare ASTH & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- OCS
- Stock Information
- Founded
- ASTH 1994
- OCS 2003
- Country
- ASTH United States
- OCS Switzerland
- Employees
- ASTH N/A
- OCS N/A
- Industry
- ASTH Professional Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- OCS Health Care
- Exchange
- ASTH Nasdaq
- OCS Nasdaq
- Market Cap
- ASTH 1.1B
- OCS 1.0B
- IPO Year
- ASTH N/A
- OCS N/A
- Fundamental
- Price
- ASTH $23.11
- OCS $18.81
- Analyst Decision
- ASTH Strong Buy
- OCS Strong Buy
- Analyst Count
- ASTH 8
- OCS 5
- Target Price
- ASTH $43.00
- OCS $39.80
- AVG Volume (30 Days)
- ASTH 626.8K
- OCS 131.0K
- Earning Date
- ASTH 11-06-2025
- OCS 11-10-2025
- Dividend Yield
- ASTH N/A
- OCS N/A
- EPS Growth
- ASTH N/A
- OCS N/A
- EPS
- ASTH 0.20
- OCS N/A
- Revenue
- ASTH $2,896,452,000.00
- OCS $991,999.00
- Revenue This Year
- ASTH $60.87
- OCS $32.89
- Revenue Next Year
- ASTH $27.04
- OCS $1,043.16
- P/E Ratio
- ASTH $117.98
- OCS N/A
- Revenue Growth
- ASTH 68.17
- OCS N/A
- 52 Week Low
- ASTH $20.12
- OCS $14.00
- 52 Week High
- ASTH $45.16
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ASTH 39.76
- OCS 41.08
- Support Level
- ASTH $20.12
- OCS $19.07
- Resistance Level
- ASTH $24.50
- OCS $19.43
- Average True Range (ATR)
- ASTH 1.84
- OCS 0.45
- MACD
- ASTH -0.04
- OCS -0.05
- Stochastic Oscillator
- ASTH 27.36
- OCS 10.75
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.